Herceptin

New cancer biosimilar could net major salesA new biosimilar to the cancer drug Herceptin, which raked in $2.5 billion in US sales last year, is expected to produce blockbuster sales in the US.
Brace for a barrage of biosimilarsThe next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.
CVS, Express Scripts plan value-based drug pricingThe approaches reflect a growing number of initiatives meant to tie drug prices to value. Find out more.
Cancer drugs move to specialty distributors draws protestA national survey of pharmacy professionals released March 3 found that Genentech's decision to move three primary cancer drugs to specialty drug distribution has resulted in higher costs to hospitals and reduced availability of the medications.
Hospital pharmacists protest higher cancer drug costs in surveyA national survey of pharmacy professionals released March 3 found that a move to specialty drug distribution of three primary cancer drugs is resulting in higher costs to hospitals and reduced availability of the medications.
Unprecedented efficacy of latest HER2-targeting agents can extend life but at significant costBreast cancer is the second most common cancer in the world, and the most common cancer in women. In 2013, approximately 261,000 women were diagnosed with this disease in the United States alone.1 When diagnosed in the earliest stages, such as ductal carcinoma in situ and stage 1, the 5-year survival rate is almost 100%. If diagnosed later, or if the disease progresses to advanced breast cancer, survival rapidly decreases. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer represents about 20% of cases, and before the introduction of HER2-targeting therapies, had the worst prognosis of all breast cancer subtypes.
Distribution changes for top cancer drugs cause hospitals to protestGenentech has announced a major change in the distribution process for their 3 top cancer drugs: Avastin (bevacizumab), Herceptin (trastuzumab), and Rituxan (rituximab). Now, distribution of the drugs to hospitals and clinics will be restricted to authorized specialty distributors.
Breast cancer drug may play role in bladder cancerMayo Clinic researchers have found amplification of HER2, a known driver of some breast cancers, in micropapillary urothelial carcinoma and have shown that the presence of HER2 amplification is associated with particularly aggressive tumors.